 |
- Funding is part of the call for proposals "Innovations in Biotherapies and Bioproduction," coordinated by the Health Innovation Agency under France 2030 strategy, operated on behalf of the French government by Bpifrance
PARIS, May 13, 2025 /PRNewswire/ -- Eligo Bioscience, a biotechnology company pioneering the development of novel genetic medicines, today announced it has secured a $5 million grant from the French government to accelerate the advancement and scaling up of Eligo's proprietary topical gene delivery platform, designed to enable local production of therapeutic biologics directly by skin-resident bacteria.
This grant follows recent key milestones for Eligo, including the publication of its microbiome base-editing platform in Nature, securing multiple foundational patents covering in situ editing of the skin microbiome, and successfully expanding its Series B funding round to $35 million. This latest non-dilutive financial support strengthens Eligo's capacity to rapidly advance its clinical pipeline.
Scaling up and advancing towards the clinic
Building on the development of its first-generation CRISPR-based topical therapeutic targeting moderate to severe acne vulgaris, Eligo will now optimize and scale up the bioproduction process of its innovative gene delivery vector ahead of later-stage clinical trials. In this endeavor, Eligo is partnering with Biose Industries, a globally recognized CDMO specializing in microbial fermentation. Biose's extensive GMP expertise in scaling complex microbial therapeutics will be instrumental in accelerating Eligo's progress toward clinical validation.
"This funding empowers us to establish a robust bioproduction process for our first-in-class topical microbiome-targeting gene-editing therapies, laying the groundwork for expanding into a wide range of immuno-dermatological indications," said Dr. Xavier Duportet, CEO and Co-Founder of Eligo Bioscience. "It reinforces our ambition to deliver truly transformative therapeutic solutions, addressing critical medical challenges faced by millions of patients worldwide."
Expansion to immuno-dermatology targets
The skin microbiome plays a pivotal role in cutaneous immune regulation, and commensal bacteria residing within the hair follicle lie in immediate proximity to resident immune cells.
Eligo's unique in-situ delivery modality enables to perform in-situ genetic engineering of these commensal bacteria, turning them as localized bioreactors that can express high-potency biologics precisely where immune dysregulation occurs.
The new funding will support the exploration of multiple therapeutic payloads and the build-out of a diversified immuno-dermatology pipeline targeting chronic inflammatory and immune-mediated skin diseases with significant unmet need.
For more information about Eligo Bioscience, France 2030, and Bpifrance: eligo.bio/france2030.
Contact :
press@eligo-bioscience.com
- Funding is part of the call for proposals "Innovations in Biotherapies and Bioproduction," coordinated by the Health Innovation Agency under France 2030 strategy, operated on behalf of the French government by Bpifrance
PARIS, May 13, 2025 /PRNewswire/ -- Eligo Bioscience, a biotechnology company pioneering the development of novel genetic medicines, today announced it has secured a $5 million grant from the French government to accelerate the advancement and scaling up of Eligo's proprietary topical gene delivery platform, designed to enable local production of therapeutic biologics directly by skin-resident bacteria.
This grant follows recent key milestones for Eligo, including the publication of its microbiome base-editing platform in Nature, securing multiple foundational patents covering in situ editing of the skin microbiome, and successfully expanding its Series B funding round to $35 million. This latest non-dilutive financial support strengthens Eligo's capacity to rapidly advance its clinical pipeline.
Scaling up and advancing towards the clinic
Building on the development of its first-generation CRISPR-based topical therapeutic targeting moderate to severe acne vulgaris, Eligo will now optimize and scale up the bioproduction process of its innovative gene delivery vector ahead of later-stage clinical trials. In this endeavor, Eligo is partnering with Biose Industries, a globally recognized CDMO specializing in microbial fermentation. Biose's extensive GMP expertise in scaling complex microbial therapeutics will be instrumental in accelerating Eligo's progress toward clinical validation.
"This funding empowers us to establish a robust bioproduction process for our first-in-class topical microbiome-targeting gene-editing therapies, laying the groundwork for expanding into a wide range of immuno-dermatological indications," said Dr. Xavier Duportet, CEO and Co-Founder of Eligo Bioscience. "It reinforces our ambition to deliver truly transformative therapeutic solutions, addressing critical medical challenges faced by millions of patients worldwide."
Expansion to immuno-dermatology targets
The skin microbiome plays a pivotal role in cutaneous immune regulation, and commensal bacteria residing within the hair follicle lie in immediate proximity to resident immune cells.
Eligo's unique in-situ delivery modality enables to perform in-situ genetic engineering of these commensal bacteria, turning them as localized bioreactors that can express high-potency biologics precisely where immune dysregulation occurs.
The new funding will support the exploration of multiple therapeutic payloads and the build-out of a diversified immuno-dermatology pipeline targeting chronic inflammatory and immune-mediated skin diseases with significant unmet need.
For more information about Eligo Bioscience, France 2030, and Bpifrance: eligo.bio/france2030.
Contact :
press@eligo-bioscience.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology
SANYA, China, Jan. 16, 2026 /PRNewswire/ -- Orange Lion Sports (formerly Alibaba Sports), a global sports event operator, is redefining how major athletic competitions and tourism converge through the coordinated integration of digital platforms and consumer services. The recent 2025 Hainan (Sanya) Marathon, supported by the company, showcased an "event-as-journey" experience that delivered a professionally operated, high-quality racing platform while supporting measurable economic growth for the host city. The marathon saw hotel occupancy in Sanya soar to 92%, with a notable 35% surge in spending at local businesses along the race route, establishing a promising blueprint for the scalable "racecation" model.
"We are committed to creating lasting value for athletes and sports enthusiasts," said Yang Yong, General Manager of Events and Commercialization at event partner Orange Lion Sports. "We activated resources across the Alibaba ecosystem, including Taobao, Fliggy, Alibaba Health, Ant Chain, and Amap, to extend engagement beyond race day. This approach attracted runners from across Hainan, other parts of China, and overseas, while encouraging additional event-related spending."
The provincial tourism and sports department has introduced funding incentives for 2026 sports events to attract national and international competitions. Orange Lion Sports has demonstrated how large-scale events can generate sustained economic activity and benefit local businesses by digitally integrating dining, lodging, transportation, entertainment, and shopping. In partnership with Taobao, the company launched a "Winter Warm-up Festival" that distributed tailored promotional vouchers and offers ahead of the event, designed to connect race participation with consumer engagement by introducing regional culinary specialties such as fermented vinegar hot pot and traditional Li-Miao cuisine to runners across China.
The economic benefits were sustained beyond the race period. According to Fliggy data, hotel bookings in Sanya began rising steadily from late October 2025, when event promotions launched, and remained strong throughout the marathon period. The momentum extended beyond the race, coinciding with the New Year holiday travel period. Data from the Sanya tourism bureau shows that during the 2026 New Year holiday, the city welcomed 650,800 visitor arrivals, with tourism revenue of 1.299 billion yuan (approx. US$186 million) generated, illustrating the role of the "racecation" model in supporting tourism demand.
In the future, Orange Lion Sports will harness AI technology to enhance sports events and promote fitness for all, in line with their assertion at CES in 2017: AI is the future of sports development.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Harnessing the Power of Sports: Orange Lion Sports Leads the Way in Driving the Emerging Trend of "Racecation"
